A new drug to treat diabetic kidney disease? Taubman Scholar Dr. Frank Brosius partners in clincial trial

With almost 2 million new cases diagnosed each year, more than 8% of the U.S. population has diabetes. And roughly 30% will eventually develop diabetic kidney disease.

Researchers at the University of Michigan Medical School are partnering with Eli Lilly and Company in using a human genome-wide data set, together with mouse models, to identify a key driver of diabetic kidney disease. 

Sponsored by Lilly, a new clinical study will examine whether a drug being developed to treat arthritis and skin diseases can be repurposed to help prevent progression of diabetic kidney disease. It takes advantage of genome-wide expression data analyzed by Matthias Kretzler, M.D., Frank Brosius, M.D. and their teams, as well as the investigators’ expertise in animal models of diabetic complications.

"We prioritized this pathway as the most relevant in diabetic nephropathy," said Kretzler. "Together with data from model systems published, there was such strong evidence that Lilly repurposed their compound and started a phase II trial in less than 15 months. It’s exciting because this kind of collaboration between industry and academia is exactly the way we can accelerate new therapies to help patients."

Kretzler is widely recognized for international multicenter studies of genome-wide expression profiles of major diseases affecting human kidneys including diabetes, hypertension and autoimmune diseases like lupus.

"Dr. Kretzler put together a network of research teams to establish a worldwide human genome-wide renal gene expression consortium,” noted Brosius, whose lab is one of 12 organizations participating in the NIH-sponsored Animal Models of Diabetic Complications Consortium. "Then my group provided the animal model studies and the in-depth understanding of diabetic complications that allowed us to focus on the pathway. This highly collaborative approach makes the U-M one of the only places in the world with the combined expertise to move this project forward."


Help Us Make A Difference. Make A Donation That Could Save Lives.

Make A Gift


Follow Us / Friend Us

Discovery-driven research that matters


Taubman Scholar Dr. Charles Burant tests promising diabetes drug

TAK-875, a new treatment for type 2 diabetes, improves blood sugar control and is equally effective as glimepiride, but has a significantly lower risk of creating a dangerous drop in blood sugar, called hypoglycemia, according to a new study.

Read more

Taubman Institute leaders make the case for more doctor-scientist funding


The prestigious "Academic Medicine" journal has just published a new article authored by Taubman Institute senior management and Detroit-area attorney Scott Roberts.

The article explores the problematic gap between bench research and clinical application of new treatments or cures. 

Read more

Help Us Make A Difference. Make A Gift.

Leaders from the realms of business, academia and the community help to refine the Taubman Institute's vision, to monitor progress and to provide support, advice and counsel.

Meet the Leadership Advisory Board

Meet the Scientific Advisory Board

About Taubman Institute Video

In this video feature, Taubman Scholars explain why funding for high-risk research is so important to their work and to the discovery of promising cures and treatments.  


Stem cell surgery targets ALS Video

Patients glean hope from trial’s progress but wish it were faster


video-emerging-scholars-programDonors pitch in to keep brilliant science minds at U-M Video

Emerging Scholars program connects promising M.D.-researchers with philanthropists